The recent introduction of patients with VEXAS syndrome as a unique and distinct entity of patients with hematologic disorders in association with inflammatory/autoimmune phenomena, prompted us to perform a Sanger sequencing analysis to be able to exclude mutations in the UBA1 gene, which are considered as pathognomonic alterations of VEXAS syndrome. The gene discussed is UBA1; the disease is hematologic disorder.